--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About MREO20260515C0.5
Pharmaceutical
Mereo BioPharma Group plc was incorporated under the laws of England and Wales on 10 March 2015. The company is a biopharmaceutical company focused on the development of innovative therapies for rare diseases. It has established a portfolio of late-stage clinical candidates, including setrusumab for osteogenesis imperfecta and alvelestat for α-1 antitrypsin deficiency-related lung disease. The company's strategy involves the selective acquisition and development of rare disease product candidates that have progressed through prior research and development.
